RealTime Dynamix: Multiple Sclerosis Q1 2017

This Spherix Global Insights report highlights responses from 101 neurologists about the evolving treatment patterns for disease-modifying therapies in MS. Emphasis on market shifts resulting from the introduction of Glatopa, the first generic DMT to enter the market, early indicators of likely uptake of Roche’s Ocrevus including which DMTs face the greatest threat and the increasing use of oral DMTs as first line options.

Click the button below to download highlights from this report.

RTD: Multiple Sclerosis Spotlight

2017-06-18T12:58:42+00:00